Profound Medical Corp Aktie News

Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy

Profound Medical Corp. ( PRN:CA ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Stephen Kilmer - Investor Relations Rashed Dewan Mathieu Burtnyk - President Thomas Tamberrino - Chief Commercial Officer Arun Menawat - Chairman of the Board & CEO Conference Call Participants Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division John McAulay - Stifel, Nic...

TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the third quarter ended September 30, 2025. Unless specified otherwise, all a...

TORONTO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO® system with Getz ...

Agreement creates runway for Profound's incision-free and radiation-free therapies for the ablation of diseased tissue, to penetrate the largest healthcare market in the Middle East

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the Stifel 2025 Healthcare Conference ...

To release full third quarter 2025 financial results on November 13th; conference call to follow To release full third quarter 2025 financial results on November 13th; conference call to follow

New program delivers TULSA Procedure's precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas New program delivers TULSA Procedure's precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas